Biotechnology

Wuhan General Group Inc Cancels 5,000,000 Common Shares

November 22, 2021 8:30 AM

CAPE TOWN, SA / ACCESSWIRE / November 22, 2021 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("WGG'' or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to share the following update: M2Bio Sciences is pleased to announce that 5,000,000 common shares held by the previous CEO have been cancelled. The company has reduced its share capital by 9%. The total number of...

Read more

Biovica’s DiviTum(R)TKa in Three Studies at SABCS 2021

November 19, 2021 10:15 AM

UPPSALA, SE / ACCESSWIRE / November 19, 2021 / Biovica International (STO:BIOVIC-B) (STO:BIOVIC.B) (FRA:9II) Biovica, active in cancer diagnostics, today announced that results from three different studies using DiviTum®TKa, including a budget impact model, will be presented at the world's largest breast cancer symposium, San Antonio Breast Cancer Symposium (SABCS), in early December. The studies are of a next generation CDK inhibitor,...

Read more

Dermata Announces Positive Results from DMT410 Phase 1b Proof of Concept Study for Aesthetic Skin Conditions

November 19, 2021 8:30 AM

Observed improvements in pore size, luminosity, brightness, and overall aesthetic appearance Duration of effect lasted approximately 3 months No potential distant spread of toxin observed SAN DIEGO, CA / ACCESSWIRE / November 19, 2021 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (NASDAQ:DRMA), a clinical-stage biotechnology company focused on the treatment of medical and aesthetic skin conditions, today announced positive efficacy...

Read more

ITOCO Launches Its Nopal Cactus Carbon Capture Program in Portugal Through a Joint Venture with LATINCHOICE-UNIPESSOAL LDA

November 18, 2021 11:20 AM

TORONTO, ON / ACCESSWIRE / November 18, 2021 / ITOCO INC. (OTC PINK:ITMC) ITOCO is pleased to announce it has selected LATINCHOICE - UNIPESSOAL LDA. in Portugal to Joint Venture as it expands its Nopal Cactus Carbon Capture Program internationally. The ITOCO Nopal Cactus Carbon Capture Program has been developed with great success in Mexico. The program captures Carbon from the atmosphere permanently via the Nopal Cactus, while at the same time...

Read more

Vitro Biopharma Receives FDA Authorization to Conduct a Clinical Trial Using AlloRx Stem Cells(R) to Treat Pitt Hopkins Syndrome, a rare form of Autism

November 17, 2021 4:10 PM

GOLDEN, CO / ACCESSWIRE / November 17, 2021 / Vitro Biopharma, Inc. announced receipt of FDA authorization and clearance to enroll patients in its IND for a phase I-II, randomized, double-blind, placebo-controlled study of the safety and efficacy of therapeutic treatment with AlloRx Stem Cells® in children with Pitt Hopkins Syndrome (PTHS), a rare neurogenetic disorder that features autistic traits. PTHS results from genetic mutations/deletions...

Read more

Pressure BioSciences, Inc. Q3 Financial Results Maintain Solid 2021 YTD Growth

November 17, 2021 9:23 AM

Operational and Technical Achievements Set Stage for Expected Major Growth and Profitability in 2022 Investor Call Scheduled for Wednesday, November 17, 2021 at 4:30 p.m. ET SOUTH EASTON, MA / ACCESSWIRE / November 17, 2021 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide...

Read more

Enzolytics, Inc. Announces Production and Sale in North America of "Enzolytics IPF Immune", a Tested Immune Modulator based on U.S. Patent No. 8,309,072

November 17, 2021 8:00 AM

COLLEGE STATION, TX / ACCESSWIRE / November 17, 2021 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/) has announced planned production and sale in the U.S. and North America of "Enzolytics IPF Immune", a liquid nutritional supplement that is an immune modulator that benefits the immune system by fortifying it against infections and supporting the body's antioxidant defense. The active components in the supplement have been registered...

Read more

Dermata Announces First Patient Enrolled in its Phase 2 Trial of DMT310 for the Treatment of Moderate-to-Severe Rosacea

November 17, 2021 8:00 AM

Topline results expected in second half of 2022 Rosacea affects about 16 million patients in the U.S. SAN DIEGO, CA / ACCESSWIRE / November 17, 2021 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (Nasdaq:DRMA), a clinical-stage biotechnology company focused on the development of novel dermatology therapies for the medial and aesthetic markets, today announced it has enrolled the first patient in its Phase 2 trial of DMT310 for the...

Read more

Viewpoint Molecular Targeting(R) Enters Agreement with UK-Based National Nuclear Laboratory, Ltd. to Advance Development of Targeted Alpha Therapy for Cancer

November 16, 2021 10:00 AM

Viewpoint is focused on solidifying a global [212Pb] supply strategy through relationship building from research through commercialization Agreement significantly expands Company's network of researchers and clinicians in the UK and Europe CORALVILLE, IA / ACCESSWIRE / November 16, 2021 / Viewpoint Molecular Targeting, Inc. ("Viewpoint" or the "Company"), a radiopharmaceutical company developing precision lead-212-based α-particle oncology...

Read more

Thermic Science Releases 2021 Year-End Guidance with Positive Exchange Filings Communications, Positive Cannabis Science Acquisition Updates, Exciting CSi-EDP Crypto Currency Eco System Initiatives, and New Thermic IR Heater Product Lines

November 16, 2021 9:20 AM

NASHVILLE, TN / ACCESSWIRE / November 16, 2021 / Thermic Science International Corporation, formerly known as Omnicanna Health Solutions, Inc. aka ENDOCAN CORP. (WKN: A1W61J, ISIN: US29271J1097, OTC PINK:ENDO), is pleased to announce that the Company is growing a very strong "people/shareholder orientated", conglomerate organization. Join in with 1,000's of real people and 1,000's of real shareholders Worldwide supporting Economic Development...

Read more

enVVeno Medical to Present at the Virtual Investor Roundtable Event

November 16, 2021 8:20 AM

- Live moderated video webcast discussion with CEO Robert Berman and Marc Glickman, M.D., Senior Vice President and Chief Medical Officer of enVVeno on Tuesday, November 16th at 1:00 PM ET IRVINE, CA / ACCESSWIRE / November 16, 2021 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that Robert Berman, CEO and Marc Glickman, M.D.,...

Read more

Applied UV Reports Third Quarter 2021 Results

November 16, 2021 7:00 AM

Results: Revenue increased 88.5% to $3.55 million as compared to $1.88 in the previous quarter Gross profit increased to $1.0 million, or 29.6% vs. sales as compared to $0.5m, or 28.3% vs. sales in the previous quarter Net loss improved 49% to $(1,080,805) as compared to a net loss of $(2,138,231) in the previous quarter Net loss per share improved to $(0.14), inclusive of preferred dividends of $241,500, as compared to a net loss per share of...

Read more

CB Scientific Files Application to Uplist to the OTCQB Venture Market

November 16, 2021 6:00 AM

Upgraded listing would provide increased transparency and enhanced trading efficiency ESCONDIDO, CA / ACCESSWIRE / November 16, 2021 / CB Scientific. Inc. (OTC PINK:CBSC) ("CBSC" or the "Company") is pleased to announce that it has submitted its application to uplist to the OTCQB® Venture Market. The application itself is not a guarantee of acceptance by OTC MARKETS to go from the Company's current OTC PINK status to uplisting onto the OTCQB®....

Read more

Biovica’s DiviTum(R)TKa Results Published in Journal of Medical Economics

November 16, 2021 3:35 AM

UPPSALA, SWEDEN / ACCESSWIRE / November 16, 2021 / Biovica International (STO:BIOVIC-B) (STO:BIOVIC.B) (FRA:9II) Biovica, active in cancer diagnostics, today announced that the results of a DiviTum®TKa budget impact model have been published in the Journal of Medical Economics. This publication expands on data presented at the ISPOR 2021 meeting. The model's results show that monitoring with DiviTum®TKa may achieve savings of up to three times...

Read more

American CryoStem to Study New Standardized Treatment Protocols for Wound Healing

November 16, 2021 1:00 AM

EATONTOWN, NJ / ACCESSWIRE / November 16, 2021 / American CryoStem Corporation (OTC PINK:CRYO), a clinical stage biotechnology company, global licensor and a pioneer in autologous cellular processing and therapies announced today that it has completed the development of a new standardized wound healing protocol utilizing its tissue based technologies with Advanced Regenerative Associates (Tinton Falls, NJ). The Company's wound healing...

Read more

Helix BioPharma Corp. Provides Second Bi-Weekly MCTO Status Update

November 15, 2021 6:15 PM

RICHMOND HILL, ON / ACCESSWIRE / November 15, 2021 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is providing this bi-weekly update on the status of the management cease trade order granted on November 1, 2021 (the "MCTO") by its principal regulator, the Ontario Securities Commission under National Policy 12-203 Management...

Read more

Dermata Therapeutics, Inc. Reports Third Quarter 2021 Financial Results and Provides Corporate Update

November 15, 2021 4:01 PM

- Announced positive topline results from DMT310 proof of concept (POC) study in mild-to-moderate psoriasis - - Closed upsized $18.0 million initial public offering (IPO) on Nasdaq Capital Market - - Topline results from DMT410 POC study in multiple aesthetic skin conditions to be presented November 19, 2021 - - On track to initiate DMT310 Phase 2 study for moderate-to-severe rosacea in Q4 2021 - SAN DIEGO, CA / ACCESSWIRE / November 15, 2021 /...

Read more

RedHill Biopharma Ltd Announces RedHill: LPI in Part A of RHB-107 P2/3 COVID Study

November 15, 2021 7:02 AM

RedHill Biopharma Announces Last Patient Randomized in Part A of Ongoing Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients Recruitment completed for Part A of the Phase 2/3 study of once-daily orally-administered RHB-107 (upamostat) for patients with symptomatic COVID-19 who do not require hospital care Top-line results for Part A of the study, designed to evaluate safety and tolerability of RHB-107 and dose...

Read more

Apollo Endosurgery to Present at Four Upcoming Investor Conferences

November 12, 2021 9:00 AM

AUSTIN, TX / ACCESSWIRE / November 12, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced that management will participate in four upcoming investor conference events. Conferences Apollo Endosurgery management will participate include: Monday, November 15, 2021 Stifel 2021 Healthcare Conference (Virtual) Management will...

Read more

EV Biologics Updates on NFT Dividend

November 12, 2021 8:45 AM

NASHVILLE, TN / ACCESSWIRE / November 12, 2021 / EV Biologics Corp, (OTC PINK:YECO), today updated shareholders with further details about its NFT dividend. The Company is still awaiting approval from FINRA for the distribution of the dividend. This is the first time that any public company has attempted to distribute a NFT digital asset as a dividend. As soon as FINRA approves the distribution of the dividend, the Company will issue the NFT to...

Read more